Study finds large increase in Type 1 and Type 2 diabetes in youth
CHICAGO — In a study released Saturday that included data from more than 3 million children and adolescents from diverse geographic regions of the United States, researchers found that the prevalence of both Type 1 and Type 2 diabetes increased significantly between 2001 and 2009. The study was published in the May 7 issue of JAMA, a theme issue on child health. This issue was released early to coincide with the Pediatric Academic Societies Annual Meeting.
"Understanding changes in prevalence according to population subgroups is important to inform clinicians about care that will be needed for the pediatric population living with diabetes and may provide direction for other studies designed to determine the causes of the observed changes," noted lead author Dana Dabelea of the Colorado School of Public Health.
The analysis included cases of physician-diagnosed Type 1 diabetes in youth ages 0 through 19 years and Type 2 diabetes in youth 10 through 19 years of age in 2001 and 2009. The study population came from five centers located in California, Colorado, Ohio, South Carolina and Washington, as well as data from selected American Indian reservations in Arizona and New Mexico.
In 2001, the prevalence of Type 1 diabetes among a population of 3.3 million was 1.48 per 1,000, which increased to 1.93 per 1,000 among 3.4 million youth in 2009, which, after adjustment, indicated an increase of 21% over the 8-year period. The greatest prevalence increase was observed in youth 15 through 19 years of age. Increases were observed in both sexes and in white, black, Hispanic and Asian Pacific Islander youth. "Historically, Type 1 diabetes has been considered a disease that affects primarily white youth; however, our findings highlight the increasing burden of Type 1 diabetes experienced by youth of minority racial/ethnic groups as well," Dabelea said.
The overall prevalence of Type 2 diabetes for youth ages 10 years to 19 years increased by an estimated 30.5% between 2001 and 2009 — among a population of 1.7 million and 1.8 million youth, respectively. Increases occurred in white, Hispanic and black youth, whereas no changes were found in Asian Pacific Islander and American Indian youth. A significant increase was seen in both sexes and all age groups.
"The increases in prevalence reported herein are important because such youth with diabetes will enter adulthood with several years of disease duration, difficulty in treatment, an increased risk of early complications, and increased frequency of diabetes during reproductive years, which may further increase diabetes in the next generation," Dabelea wrote. "Further studies are required to determine the causes of these increases."
Axium Healthcare Pharmacy accepted into the GlaxoSmithKline Oncology network
LAKE MARY, Fla. — Axium Healthcare Pharmacy on Tuesday announced that it has been accepted into the GlaxoSmithKline Oncology network.
“For years, Axium Healthcare Pharmacy’s OncologyVisions program has made it easier for patients and providers around the country to achieve better outcomes in cancer care," stated Mark Montgomery, Axium Healthcare Pharmacy president and CEO. "As an authorized GSK Oncology Network specialty pharmacy, Axium is well-positioned to provide practices and patients with the highly-personalized care, clinical support and ongoing patient management we’ve become known for.”
As a GSK-authorized specialty pharmacy, Axium will expand its oncology therapy management focus with the addition of the following GSK oral oncology specialty medications — Hycamtin (topotecan) capsules; Mekinist (trametinib) tablets; Tafinlar (dabrafenib) capsules; Promacta (eltrombopag) tablets; Tykerb (lapatinib) tablets; and Votrient (pazopanib) tablets.
Nexium 24HR to launch late May
NEW YORK — Pfizer’s Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.
"[The Nexium] approval represents the first significant milestone in executing our Rx-to-OTC strategy," reported Albert Bouria, Pfizer president of vaccines, oncology and consumer.
The Food and Drug Administration in March approved over-the-counter Nexium 24HR (esomeprazole 20mg). In 2012, Pfizer acquired exclusive global rights from AstraZeneca to market non-prescription Nexium.